JP2005508323A - 癌治療のための医薬組成物及び方法 - Google Patents

癌治療のための医薬組成物及び方法 Download PDF

Info

Publication number
JP2005508323A
JP2005508323A JP2003530220A JP2003530220A JP2005508323A JP 2005508323 A JP2005508323 A JP 2005508323A JP 2003530220 A JP2003530220 A JP 2003530220A JP 2003530220 A JP2003530220 A JP 2003530220A JP 2005508323 A JP2005508323 A JP 2005508323A
Authority
JP
Japan
Prior art keywords
ifn
paclitaxel
cancer
chemotherapy
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003530220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508323A5 (enExample
Inventor
ダブリュ． エムレン，ジェイムズ
エフ．ジー． トリーガー，ブレント
Original Assignee
インターミューン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターミューン インコーポレイテッド filed Critical インターミューン インコーポレイテッド
Publication of JP2005508323A publication Critical patent/JP2005508323A/ja
Publication of JP2005508323A5 publication Critical patent/JP2005508323A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2003530220A 2001-09-26 2002-09-26 癌治療のための医薬組成物及び方法 Withdrawn JP2005508323A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32524601P 2001-09-26 2001-09-26
PCT/US2002/030621 WO2003026581A2 (en) 2001-09-26 2002-09-26 Pharmaceutical compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2005508323A true JP2005508323A (ja) 2005-03-31
JP2005508323A5 JP2005508323A5 (enExample) 2006-01-05

Family

ID=23267053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530220A Withdrawn JP2005508323A (ja) 2001-09-26 2002-09-26 癌治療のための医薬組成物及び方法

Country Status (5)

Country Link
US (1) US20040191218A1 (enExample)
EP (1) EP1435965A4 (enExample)
JP (1) JP2005508323A (enExample)
AU (1) AU2002337713A1 (enExample)
WO (1) WO2003026581A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014129416A (ja) * 2006-10-06 2014-07-10 Bavarian Nordic Inc Ｍｖａを使ってがんを処置する方法
WO2024034606A1 (ja) * 2022-08-10 2024-02-15 学校法人日本大学 試料の検査方法、婦人科癌及びその前癌病変の検査キット及び医薬
JP2024025634A (ja) * 2022-08-10 2024-02-26 学校法人日本大学 試料の検査方法、婦人科癌及びその前癌病変の検査キット及び医薬

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
RU2346692C2 (ru) * 2007-03-29 2009-02-20 Ефаг АО Применение 9-оксоакридин-10-уксусной кислоты, ее солей и сложных эфиров в комбинированной терапии рака яичников, способ лечения и наборы
KR20170082537A (ko) * 2014-11-14 2017-07-14 제넨테크, 인크. Vegf 길항제에 대한 반응 예측
CN105726475B (zh) * 2016-04-12 2018-05-04 青岛市妇女儿童医院 一种治疗晚期卵巢癌的注射液及其制备方法
CN105726474B (zh) * 2016-04-12 2018-04-13 周英杰 一种用于治疗晚期卵巢癌的注射液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588505A5 (enExample) * 1972-06-08 1977-06-15 Research Corp
US4657927A (en) * 1978-05-04 1987-04-14 Research Corporation Malonato platinum compounds
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5440056A (en) * 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014129416A (ja) * 2006-10-06 2014-07-10 Bavarian Nordic Inc Ｍｖａを使ってがんを処置する方法
WO2024034606A1 (ja) * 2022-08-10 2024-02-15 学校法人日本大学 試料の検査方法、婦人科癌及びその前癌病変の検査キット及び医薬
JP2024025634A (ja) * 2022-08-10 2024-02-26 学校法人日本大学 試料の検査方法、婦人科癌及びその前癌病変の検査キット及び医薬
JP7716691B2 (ja) 2022-08-10 2025-08-01 学校法人日本大学 試料の検査方法、婦人科癌及びその前癌病変の検査キット及び医薬

Also Published As

Publication number Publication date
WO2003026581A3 (en) 2004-03-04
EP1435965A2 (en) 2004-07-14
AU2002337713A1 (en) 2003-04-07
EP1435965A4 (en) 2005-09-21
WO2003026581A2 (en) 2003-04-03
US20040191218A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
JP5120368B2 (ja) 抗腫瘍剤
Choy et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
US8703709B2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
JP2020524694A5 (enExample)
US8729023B2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers
JP2005508323A (ja) 癌治療のための医薬組成物及び方法
Agarwala et al. Interferons in the therapy of solid tumors
US8026216B2 (en) Methods and compositions for contributing to the treatment of cancers
WO2006091767A2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
Locke et al. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma
US20150238460A1 (en) Methods and Compositions For Treating Hepatocellular Carcinoma
EP4431152A1 (en) Combinations of an anti-interleukin-6 receptor antibody, a platinum-based antineoplastic drug, and a taxane
US20240307530A1 (en) Combinations of an anti-interleukin-6 receptor antibody, a platinum-based antineoplastic drug, and a taxane
WO2024194261A1 (en) Combinations of an anti-interleukin-6 receptor antibody, a platinum-based antineoplastic drug, and a taxane
Shin et al. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma
Tokajuk et al. Continuation of trastuzumab-based therapy beyond disease progression in metastatic breast cancer patients–a retrospective one center analysis
JP5503528B2 (ja) 癌の処置に寄与する方法および組成物
Haslbauer Continued trastuzumab therapy for patients with HER2-positive breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050922

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060824